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https://doi.org/10.1186/s12888-018-1907-4RESEARCH ARTICLE Open AccessMedication review plus person-centred care:
a feasibility study of a pharmacy-health
psychology dual intervention to improve
care for people living with dementia
Ian D Maidment1* , Sarah Damery2, Niyah Campbell1, Nichola Seare3, Chris Fox4, Steve Iliffe5, Andrea Hilton6,
Graeme Brown7, Nigel Barnes7, Jane Wilcock5, Emma Randle8, Sarah Gillespie9, Garry Barton10 and Rachel Shaw1Abstract
Background: “Behaviour that Challenges” is common in people living with dementia, resident in care homes and
historically has been treated with anti-psychotics. However, such usage is associated with 1800 potentially
avoidable deaths annually in the UK. This study investigated the feasibility of a full clinical trial of a specialist
dementia care pharmacist medication review combined with a health psychology intervention for care staff to
limit the use of psychotropics.
This paper focuses on feasibility; including recruitment and retention, implementation of medication change
recommendations and the experiences and expectations of care staff.
Methods: West Midlands care homes and individuals meeting the inclusion criteria (dementia diagnosis;
medication for behaviour that challenges), or their personal consultee, were approached for consent.
A specialist pharmacist reviewed medication. Care home staff received an educational behaviour change
intervention in a three-hour session promoting person-centred care. Primary healthcare staff received a modified
version of the training.
The primary outcome measure was the Neuropsychiatric Inventory-Nursing Home version at 3 months. Other
outcomes included quality of life, cognition, health economics and prescribed medication. A qualitative
evaluation explored expectations and experiences of care staff.
Results: Five care homes and 34 of 108 eligible residents (31.5%) were recruited, against an original target of 45
residents across 6 care homes. Medication reviews were conducted for 29 study participants (85.3%) and the
pharmacist recommended stopping or reviewing medication in 21 cases (72.4%). Of the recommendations made,
57.1% (12 of 21) were implemented, and implementation (discontinuation) took a mean of 98.4 days. In total, 164
care staff received training and 21 were interviewed.
Care staff reported a positive experience of the intervention and post intervention adopting a more holistic
patient-centred approach.
Conclusions: The intervention contained two elements; staff training and medication review. It was feasible to
implement the staff training, and the training appeared to increase the ability and confidence of care staff to manage
behaviour that challenges without the need for medication. The medication review would require significant modification
for full trial partly related to the relatively limited uptake of the recommendations made, and delay in implementation.
Trial registration: ISRCTN58330068. Registered 15 October 2017. Retrospectively registered
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Table 1 Participant Inclusion and Exclusion Criteria
Participant Inclusion Criteria
1. Receiving medication (including but not limited to medicines in
British National Formulary [BNF 68] sections 4.1/4.2/4.3/4.11
to treat behaviour that challenges.
2. Resident within a long-term care facility.
3. Registered with a West Midlands GP (who has also agreed to
participate).
4. Dementia confirmed (dementia register, documentation of relevant
read codes, confirmation of diagnosis via communication from old
age psychiatry, memory clinic or clinical psychologist).
5. Patient, or personal consultee, willing to provide consent/assent.
6. A proxy informant (key worker or staff member with close working
relationship) who can clearly communicate in English available.
Participant Exclusion Criteria
1. Patient, or personal consultee unable or unwilling to provide
consent or lacks necessary English-language skills.
2. On palliative care register, or has pathology requiring complex
specialist medication.
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Dementia is an international healthcare priority [1, 2].
One of the key challenges within dementia care is the
management of the behavioural and psychological symp-
toms of dementia (BPSD) [3]. Behavioural symptoms in-
clude aggression, agitation, depression and hallucinations
[4]. BPSD is also referred to as behaviour that challenges,
which is defined as ‘any behaviour considered antisocial
within the care environment or deemed dangerous to the
person with dementia, their fellow residents, and staff ’ [5].
These two terms are used interchangeably in this paper.
Antipsychotics are frequently prescribed for people liv-
ing with dementia for behaviour that challenges [3]. The
usage of antipsychotics for people with BPSD is implicated
in the death of 1800 people every year and two-thirds of
such usage may be inappropriate [4]. The Banerjee Report
found antipsychotics were often used as a first solution,
yet behaviour that challenges can often be safely managed
with the use of non-pharmacological approaches [2, 4].
Senior staff in care homes should be skilled in appropriate
non-pharmacological techniques and be able to train
other staff in these techniques [2, 4].
A recent Cochrane review concluded that antipsy-
chotics could be successfully discontinued in older
people with dementia and BPSD, but the evidence was
low quality and further research was required [6].
Furthermore, solely focussing on the prescription of
antipsychotics may simply drive prescribing to equally
problematic alternative psychotropics (such as
anti-depressants and benzodiazepines) and research
should test interventions to limit the use of all psycho-
tropics [6, 7]. Secondary care specialist dementia care
pharmacists could have a vital role in ensuring the ap-
propriate use of psychotropics for BPSD [4, 8].
This feasibility study was designed to provide key in-
formation on study processes and outcomes, so that the
challenges in implementing and evaluating a
pharmacy-health psychology dual intervention could be
understood [9]. Incorporating learning from a feasibility
study can enhance the rigour and deliverability of any
subsequent full clinical trial [10, 11]. A feasibility study
was needed to assess implementation of the protocol
and estimate key parameters, such as recruitment, con-
sent and follow-up rates, and the time taken to conduct
the study, to inform the design of the main trial [9, 12].
It was also conducted to refine the battery of outcome
measures, and understand any challenges associated with
joint working between care homes, general practitioners
(GPs) and pharmacists.3. Risk of harm in line with Alzheimer's Society guidance (guidelines
published in 2011, currently being updated and therefore not
available).
4. Severe Mental Illness (e.g. schizophrenia) where psychotropic
treatment should be continued.Aim
To determine whether it is feasible to implement and
measure the effectiveness of a dual purpose pharmacy–health psychology intervention incorporating medication
review and staff training to limit the prescription of
psychotropics to manage BPSD in care home residents.
Method
Study design
An open label (non-blinded), mixed methods feasibility
study, set within the Medical Research Council (MRC)
framework for developing a complex intervention, aimed
to recruit six care homes and 45 residents [13]. The
study received ethical approval from National Research
Ethics Services (15/EM/0314); specifically the Notting-
ham 1 Committee. For detailed methods refer to the
published study protocol [7].
Setting
Care homes in the West Midlands, UK. Study conducted
from January 2015 until December 2017.
Study participants
Residents in care homes recruited were eligible if inclu-
sion criteria were met (see Table 1 for full details).
Study procedures
Identification and recruitment of care homes
The sampling frame was care homes (both nursing and
residential) in the West Midlands (within 6 miles of
Table 2 Description of dual-focused medication review-
behavioural change intervention
Behaviour Change Intervention Overview
“Inside Out” – An interactive face-to-face three-hour educational
person-centred care group based workshop, repeated twice at each
home, for care staff facilitated by a researcher with health psychology
training and experience of working in the social care sector. The main
aim of the intervention was to provide staff with the knowledge to:
• Understand that behaviours that challenge may be an expression of
unmet need
Within this the intervention aimed to provide care home staff with the
skills and resources to:
• Investigate what the unmet need might be
• Get to know the person with dementia as an individual to help
manage their behaviour
• Think creatively about how to prevent challenging behaviours by
making sure individuals’ needs are met
• Understand that behaviours that challenge are not ‘bad behaviour’
and ‘bad behaviour’ does not equate to ‘a bad person’
Training consisted of:
1. Educational elements about “behaviour that challenges”, the use of
antipsychotics to manage behaviour that challenges, good practice
guidelines to reduce psychotropics in favour of non-
pharmacological interventions.
2. Person-centred care training using the VIPS Model (V=Valuing
personhood; I=Individual needs; P=Personal perspectives; S=Social
environment), videos illustrating person-centred care practice
and practical exercises [39].
3. Information and discussion points emphasising the importance of
self-care and good communication among care staff
Primary healthcare staff received modified training primarily focussing
on the treatment of BPSD.
Summary of Medication Review (based on type 3 full clinical review)
Medication reviews were conducted by two experienced clinical
pharmacists (one who is a specialist dementia care pharmacist and
has significant experience in the clinical area) and one, who acted as
back-up and also has specialist experience in this area.
1. The primary focus is to review psychotropics used to treat
behaviours that challenge; the pharmacist will also review all other
medication as per routine care.
2. Establish therapeutic alliance with the person living with dementia
and/or their personal consultee.
3. Collect information from clinical records, care staff, GP and any
personal consultee about the patient including prescribed
treatment of BPSD, medication used to treat psychotropic induced
adverse events and any other medication.
4. Review medication, focussing on treatments for BPSD.
5. The GP was informed of the recommendations in writing; an
individualised clinical letter from the pharmacist based on a
standard proforma. The letter detailed the recommendations and
the rationale for the recommendations. This was followed up with
a phone call.
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care for people living with dementia. Care Homes meet-
ing the inclusion criteria were identified from the Care
Quality Commission (CQC) and other web-sites e.g.
Carehomes.co.uk including local authority sites. Eligible
care homes supporting the Enabling Research in Care
Homes (ENRICH; http://enrich.nihr.ac.uk/) initiative
were also identified. ENRICH is an NIHR toolkit to sup-
port research in care homes. All identified care homes
were invited to participate by letter with follow-up by
single phone call or letter to care home manager.
Recruitment of residents
Consent for residents meeting the inclusion criteria was
obtained from the resident, or their personal consultee,
someone caring for them or interested in their welfare,
but not acting in a professional capacity or for remuner-
ation. Capacity was assessed using the Mental Capacity
Act (2005) and local guidelines. All practical steps to
maximise the individual’s capacity to provide informed
consent, including taking sufficient time and the use of ap-
propriate language, were taken. If the resident lacked cap-
acity their personal consultee was approached regarding
consent to the medication review (see protocol for full de-
scription of consent; [7]). The resident’s GP was then
approached to consent to the medication review.
Recruitment of care staff
The care home manager allocated care staff to educa-
tional training sessions according to their shift patterns.
Care home managers and care staff in each care home,
and GPs who were involved in the medication review
were invited to participate in qualitative interviews for
the process evaluation.
Intervention
The intervention contained two elements (see Table 2
for summary of the content of both elements).
Outcome measures
The primary outcome measure was the Neuropsychiatric
Inventory-Nursing Home version (NPI-NH) at 3 months
[14]. This is a caregiver administered questionnaire that
assesses neuropsychiatric symptoms. Other outcomes in-
cluded quality of life (EQ-5D/DEMQoL) [15, 16], cogni-
tion (sMMSE) [17], health economics (modified version
of Client Services Receipt Inventory [CSRI]) [18] and
prescribed medication (including implementation of the
review; obtained from the care home medication rec-
ord). Data were collected at 8 weeks, and 3 and 6 months
(findings will be reported elsewhere).
An embedded process evaluation used individual semi-
structured qualitative interviews to explore theexpectations and experiences of GPs and care home
staff, including managers, both pre- and
post-intervention. In addition, the chief investigator col-
lected reflective comments from members of the team
and participants (n = 9) to inform the potential design of
the full trial. These accounts were collected during a
short (up to 15 min) phone interview, which covered
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participation in the study and implementation of the
intervention.
All care home staff who received the behaviour
change intervention were asked to complete two ques-
tionnaires. First, the Approaches to Dementia Ques-
tionnaire, which was administered pre-intervention,
immediately after the training, and 3 months
post-intervention; second, the Maslach Burnout Inven-
tory – Human Services Survey which was administered
pre- and 3 months post-intervention (findings will be
reported elsewhere).Results
Recruitment of care homes
Recruitment took far longer than expected. Recruiting
six care homes was planned to take six months; it took
14 months to recruit five care homes. Despite two
six-month extensions to the study period, it was not
possible to recruit a planned sixth care home in the time
available. Our original intention was to search the CQC
web-site electronically, using the inclusion criteria, to
identify eligible care homes. Due to the complexity of
the database this did not prove possible, and it was
necessary to look at each home individually on the
website. Local authority and commercial websites (e.g.
www.carehomes.co.uk) were searched using the same
approach.
Our revised search strategy identified 82 eligible care
homes. Three of these homes were recruited (conversion
rate = 3.7%). Subsequently the support available from
ENRICH was used; three ENRICH homes expressed an
interest and one of these was recruited [19]. One care
home was recruited by personal contacts – this home
did not respond to the initial letter and follow-up.
At individual care home level, the decision regarding
participation was largely driven by the care home man-
ager, and personal contact between the research team
and care home managers in following up initial invita-
tions to participate was effective in securing care home
sign up. The care homes recruited to the study were di-
verse (see Table 3 for further details).Table 3 Characteristics of participating care homes
ID Type Organisation
001 Nursing home Local charity with small number (< 5) of care/nursi
002 Residential home Medium sized care home chain (50 to 100 care ho
003 Nursing home Small care home chain (< 5)
004 Nursing home Single ownership
005 Nursing home Single ownershipTime to recruit care homes
The time to recruitment for care homes was calculated
according to the number of days between the initial ap-
proach from the research team to the care home man-
ager, and the receipt of local ethical approval permitting
recruitment of residents to begin in that care home. The
mean number of days taken to recruit care homes was
236.6 (SD 127.2). This was partly because of the time
taken to recruit the final two care homes: the care home
recruited via ENRICH took 314 days to recruit, and the
care home recruited via the personal contacts took
421 days. The first three care homes, which were re-
cruited following an initial letter to the care home man-
ager took a mean of 149 days (SD 31).Number/proportion of eligible residents in each care
home and resident recruitment
Across the five participating care homes, 295 potential
participants were available for eligibility screening (see
Table 4). Of these, 108 (36.6%) met the inclusion criteria.
The proportion of eligible residents varied from 29.2 to
58.1% across care homes.
Overall, 34 of the 108 residents were recruited to the
study (conversion rate = 31.5%). Recruitment rates from
individual care homes ranged from 16.7% (n = 3/18) in
care home 005 to 58.8% (n = 10/17) in care home 001.
Recruiting 34 individuals in total equates to a mean of
6.8 residents at each care home (range 3 to 10; Standard
Deviation [SD] = 3.11). The number of individuals re-
cruited to the study represented 75.6% of the original tar-
get (n = 45). Several additional potential participants were
identified in the last care home recruited, but there was
not enough time remaining in the study period to
complete follow-up so these residents were not recruited.Time to recruitment for study participants
Time to recruit study participants was calculated from the
number of days between ethical approval being granted for
recruitment to begin in each care home, and the point at
which the last participant at that care home was recruited
to the study. Time to complete participant recruitment
ranged from 117 to 349 days (mean = 219.6; SD = 84.2).Specialty Number of beds
ng homes Adults over 65 52
mes) across England Adults over 65; Dementia 64
Adults over 65; Dementia 76
Adults over 65; Dementia 72
Adults over 65; Dementia 31 dementia (45 total)
Table 4 Eligible residents in participating care homes and recruitment rate
Care Home ID Number eligible / number screened Proportion eligible (%) Number recruited Proportion of eligible residents recruited (%)
001 17/52 32.7 10/17 58.8
002 26/64 40.6 10/26 38.5
003 24/76 31.6 6/24 25.0
004 21/72 29.2 5/21 23.8
005 18/31 58.1 3/18 16.7
ALL 108/295 36.6 34/108 31.5
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Consent from each participant’s GP was required for the
medication review. Obtaining consent was straightfor-
ward in homes predominantly supported by a single
general practice with strong links between the practice
and the home (care homes 001, 003, 005). It was consid-
erably more challenging in care homes supported by
multiple practices (care home 002 supported by 4 prac-
tices and 004 by 2 practices).
In care home 002 it took over 3.5 months to obtain GP
consent for every resident and required a strategic and
time-consuming approach to primary care engagement.
This approach included working closely with the Clinical
Comissioning Group (CCG), Practice-based Pharmacists
(PBP) and NIHR Clinical Research Network (CRN) pri-
mary care leads, a newsletter about the study specifically
written for local GPs, an article in a local NIHR “Connect”
Magazine, presentation at a GP Local CRN event on
Dementia and attendance at a GP practice meeting. In
care home 004, it was impossible to obtain GP consent for
2 recruited participants, for whom the personal consultees
had assented, despite the earlier strategic approach.
Retention rates of care homes and participants
None of the five care homes withdrew from the study.
Five study withdrawals (14.7%) occurred before the
medication review could be undertaken. Further partici-
pants were withdrawn at 8 week (n = 5; NB: one of these
5 subsequently provided data at 3 and 6 months),
3 month (n = 8) and 6 month (n = 8) follow-up. Attrition
rates by care home ranged from 67 to 83.3%. Figure 1
shows participant attrition and the reasons for loss to
follow-up at each data collection point.
Medication reviews: Recommendations and
implementation
Medication reviews were conducted by specialist phar-
macists for 29/34 study participants (85.3%) (Fig. 2). A
written recommendation to stop or review medication
was made for 21/29 participants (72.4%). The recom-
mendations were implemented by the participants’ GP
in 12 of the 21 medication reviews (57.1%). There wassubstantial variability in implementation of recommen-
dations by care home, ranging from 0 to 100%. It took a
mean of 98.4 days (range 33 to 138; SD = 42.5) to imple-
ment the recommendations. The protocol was amended
so that the participant baseline assessment was repeated
if the recommendation was not implemented within
eight weeks of the medication review.
Behavioural change intervention
One hundred and forty-two care staff attended the
person-centred care workshop and received the Beha-
vourial Change Intervention across the five homes
(mean = 28.4; range 25 to 38; SD = 5.41). For further de-
tails of participation rates, see Table 5.
In addition, 22 primary care clinical staff, including
GPs (n = 14), GP trainees (n = 4), Practice Nurses (n = 3)
and PBP (n = 1) across nine practices received the modi-
fied training primarily focussing on the treatment of
BPSD. Four GPs were trained on the phone (one per
training session); whereas 18 staff received training in
five face-to-face sessions (mean of 3.6 per session).
Qualitative evaluation of expectations and experiences of
care staff
Face-to-face, semi-structured interviews were conducted
[by NC] with 21 participants (Care Home Managers
[CHM] = 5; GPs = 3; Care Staff [CS] = 13). This paper re-
ports expectations and experiences of the feasibility
study. Participants’ understanding of current guidance,
person-centred care and details of changes in percep-
tions of people with dementia will be fully reported in a
subsequent paper.
Participants found both the training and the medica-
tion review aspects of the feasibility study beneficial:
“Very useful exercise...being provided the information
it helps (to) make us sure that we’re prescribing
appropriately.” (GP1, post-intervention).
“I did ask random staff after the training and they
were all really positive, said they found it really
interesting, really helpful and I’ve actually run it past
Fig. 1 Participant retention through the study. Flow chart detailing participant retention throughout the study. * Participant who did not provide
data at 8 weeks went on to provide both 3 and 6 month data
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my training in my area and they’ve actually
sanctioned it being just as good as the (care home
company) training.” (CHM2, post-intervention).
Participants identified that after the training they were
more likely to adopt a holistic approach with less
reliance on medication:
“I think staff now discuss and think slightly different
from what they did before. Before it would be 'go to
the nurse', it would be 'what meds can we give?'
That’s still there with some but overwhelmingly it’s
'what can we do different?'” (CHM5,
postintervention).“I think there’s been very little (medication) put back.
You know sometimes when you stop things, somebody
immediately just worries about it and it just goes
straight back on but I don’t think that’s happened.”
(GP2, post-intervention).
The practical training approach promoted adoption of
patient-centred care, which underpinned this more
holistic approach to care:
“People don’t realise, a lot of time, their actions have a
reaction and having– just examples and bringing it to
the forefront of the mind, which is what the training
does…they start thinking about things a little bit
differently and I noticed that after the training the team
Ta
Ca
00
00
00
00
00
ath
Fig. 2 Consort diagram of medication review. Consort diagram detailing number of medication reviews and implementation
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what wasn’t working.” (CS13, post-intervention).
The holistic approach, to the medication review, with
the focus on quality and safety, rather than cost also
promoted adoption of the intervention:
“At the same time…a CCG pharmacist (was) going
into the home to do sort of medication reviews…more
of the point-of-view of reducing costs. Different ap-
proach from the MEDREV pharmacist…very much
geared around using the evidence to increase the qual-
ity of care...doing it for…quality and safety rather than
cost prioritisation.” (GP2, post-intervention).
GPs identified that participation placed little burden on
them, although some GPs identified barriers including
time taken to implement the medication review:
“The study was already set up to be as easy as it can
be on GP time.” (GP1, post-intervention).ble 5 Number of staff at each home participating in training and to
re Home ID Number of participating
in training
Completion rate
1 26 100%
2 25 100%
3 26 100%
4 27 100%
5 38 100%
ese figures include staff in a non-caring roles“That was just broadly because of timing and me not
being able to…do it because of lots of things that
happen in surgery.” (GP3, post-intervention).
Overall, providing care staff with additional tools and
skills to address behaviours that challenge appeared to
have a positive impact on the attitudes and practices
of care home staff:
“The care home staff have been reassured by the
training…sometimes when I’ve done medication reviews
in the past they’ve been a little bit cautious. “Oh, I don’t
think their family will like that”. “Oh, this person’s been
on it for ages”…we’ve had a little bit of resistance and
that’s gone a little bit.” (GP2, post-intervention).
“…the way that the training’s done it’s all about the VIPS
and it’s making people really think…about the individual,
what might be wrong with them, how to minimise those
challenging behaviours…it’s giving people more tools to do
their job better.” (CHM2, post-intervention).tal number of staff
Total number of staff
in care home
Proportion of staff
receiving training (%)
72 (includes staff in non-caring roles) 36.1%a
Approximately 50 carers 50%
34 76.5%
Approximately 63 staff in caring roles 42.9%
Approximately 148 staff 25.7%a
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Increasing care home research is a key priority, and
to the best of our knowledge this is the first study to
report in detail the feasibility of a dual-purpose care
home study involving staff training and medication
review. Overall, recruitment was challenging and
time-consuming, securing GP engagement was difficult,
drop-out rates were high and, where substantial recom-
mendations in relation to medication were made, these
took a long time to implement, if implemented at all.
Like other care home research, recruitment was chal-
lenging [20-23]. The CQC database, as a search engine,
had limited utility, confirming earlier findings (Personal
Communication, Analisa Smythe, 18th October, 2017). It
took 14 months rather than six months to recruit five
care homes; and like other studies, the protocol was
continually adapted as the team learnt from earlier ex-
perience [21]. This resulted in the need for five substan-
tial ethical amendments during the study, which
contributed to delays. Amendments included expanding
the recruitment area, introducing the re-baseline pro-
cedure to account for the delay in implementation and
in the final two care homes removing the six month
follow-up (due to time limitations).
Our initial response rate of 3.7% is low compared to
other studies that offered training to care homes; an-
other study had a 10% response rate [21]. This was pos-
sibly because care home managers, the key decision
makers, welcomed the offer of cost-free training, but
were less likely to welcome a medication review, which
could potentially lead to discontinuation of medication
for behaviour that challenges. Informal feedback, ob-
tained as reflective comments, from the managers and
evidence from another study confirms this viewpoint;
one observational/interview study on current practice
for the treatment of behaviours that challenge had a
similar response rate [20]. Like other studies we found
that developing local relationships and using ENRICH
were successful techniques [21].
It took a mean of 236.6 days to recruit homes. Like
other researchers, recruiting GPs from multiple practices
who provide care to participants living in a single care
home was particularly challenging [22]. Our strategic ap-
proach to GP engagement was only partially successful
and should be developed further for any larger trial.
At least 30% of residents were expected to meet the
inclusion criteria with at least 18 potential participants
per home and 7 to 8 recruited. The actual figures were
36.6% of residents with 21.6 potential participants per
home and on average 6.8 recruited. On reflection, re-
cruitment might have been improved by organising fur-
ther meetings with relatives and greater involvement of
care home staff in recruitment, although further training
may be required for the care home staff.Recent NICE guidance recommend that care providers
should provide face-to-face training and mentoring to
staff who deliver care and support to people living with
dementia [24]. This training should include the manage-
ment of behaviours that challenge including the appro-
priate use of medication [24]. MEDREV successfully
developed and evaluated an acceptable and feasible
training package, which was well received. A large num-
ber of staff (n = 164) received training about delivering
person-centred care, and the use of psychotropics and
reasons for reducing them. Furthermore, by combining
staff training with a specialist medication review, the use
of psychotropics was reduced [25].
The qualitative research and the reflective comments,
obtained from GPs were very supportive of both the
training and medication review. Staff were positive about
both elements. The Behavioural Change Intervention ap-
peared to train the care staff in person-centred care so
that they would understand why reducing psychotropics
is beneficial and support implementation of the recom-
mendations from the medication review. The pharma-
cists who trained the GPs also reported good interaction
particularly in face-to-face training, which encouraged
greater participant engagement and reached more GPs.
Nearly 43% of the recommendations (n = 9/21) were
not implemented. Other similar studies have found
similar rates; for example one study found that 58.1% of
recommendations by a clinical pharmacist were imple-
mented [26]. The reasons for this, in our study, were not
entirely clear although given the range in implementa-
tion rates between care homes, local context, and in par-
ticular the GP/care home/pharmacist relationship was
likely an important factor. Informal feedback, obtained
in the reflective comments, identified a perceived lack of
integration with other secondary care medication re-
views. The likelihood and speed of implementation may
have increased with direct communication between the
pharmacist and GP either by phone or face-to-face.
Another possible avenue to explore is utilising the model
of a practice-based pharmacist as a liaison between the
specialist pharmacists conducting the medication re-
views and the GP.
Other studies have found that GPs were broadly
supportive of pharmacist medication reviews for BPSD
and the implementation rate is similar to other studies
involving clinicians implementing recommendations
from a pharmacist [27, 28]. The relatively low uptake
could be due to the additional time and effort needed to
amend the prescription. Other studies suggest that GPs
believe reducing anti-psychotic prescribing for BPSD
could be achieved by increased availability of
non-pharmacological approaches and staffing levels [28].
Even when supported, the medication review recom-
mendations took on average 98.4 days to implement.
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also creates methodological problems for future studies:
because it was impossible to know when the recommen-
dation was likely to be implemented, collecting outcome
data was challenging. One possible reason for the delay
was the use of pre-prepared medication administration
packs, which are prepared every month, for care
homes. Care home staff also attributed the delay in im-
plementation of recommendations to a general low pri-
ority for healthcare for older people; this needs further
exploration in future research.
Whilst problems relating to medication optimisation
in care homes and in people living with dementia are
widely acknowledged, there is very little research on in-
terventions to optimise medication in care home resi-
dents [29-31]. One trial has investigated a PCT/CCG-led
medication review [32]. The homes in our study already
received regular medication reviews from CCG pharma-
cists; suggesting that CCG pharmacists may lack expert-
ise to review psychotropics. Furthermore, the GPs, in
our study, appreciated the clinical and quality focus of
the medication reviews.Limitations
This study was conducted in a single region in the UK
and had a limited number of participants. However, we
recruited and retained a range of care homes with differ-
ing characteristics (type of home, sociodemographic
characteristics of local area). The original aim was to re-
cruit a representative sample of staff from each home.
However, only three members of staff were recruited
from the final two homes, due to the difficulty and sub-
sequent delay in recruiting these homes. Only three GPs
were recruited despite efforts to recruit more. No phar-
macists were interviewed; however the feasibility issues
in relation to the medication review were captured in
the interviews with care staff and GPs, and the reflective
comments received.Policy implications
Healthcare policy must continue to focus on optimising
medication usage in care homes, including the appropri-
ate treatment of BPSD. MEDREV developed an accept-
able and feasible training programme which included
the appropriate use of medication, in line with NICE
guidance, suggesting that this may be a promising policy
approach [24]. Since this study, NHS England has
invested in pharmacy to support medication optimisa-
tion in care home [33]. This research suggests, that to
successfully optimise medication, these pharmacy staff
need to develop robust ways of working across organisa-
tional boundaries linking primary, secondary and social
care.There are also implications for research policy makers.
Recruiting the care homes and people with living de-
mentia was time-consuming and difficult, confirming
other studies. The NIHR and other funders have priori-
tised high quality research both in care homes, and on
medication optimisation in older people [31, 34]. Yet
despite this, there is limited research on medication op-
timisation in care homes [35] perhaps because care
home research involving medication optimisation is
uniquely challenging, as we found. This suggests that re-
search into medication optimisation in care homes needs
to be a specific priority.
Future research
One of the key challenges in this study was the delay in
implementation of recommendations. Whilst our solu-
tion, of repeating the baseline measurements, might
work for a single location feasibility study, when the
chief investigator is able to work closely with the Clinical
Study Officers, it is less likely to work for a larger mul-
tiple centre study. Expert recommendations on medica-
tion optimisation did not appear to be implemented in a
significant minority of residents; this needs further
investigation. From the care home point of view, it may
be a question of who has the greater authority, the GP
or the pharmacist and established relationships.
GP engagement could be improved by holding an ini-
tial event very early in the study. This event should carry
Continuing Professional Development accreditation
from the appropriate Royal College and include educa-
tion from expert speakers, ideally with international rep-
utations, in addition to information on the study.
Specialist pharmacists may not have had time to build
a good relationship with the GP and without good com-
munication and trust implementation of the recommen-
dations may be challenging as we found. Since this study
began, there has been significant investment in primary
care clinical pharmacy including within care homes
[36-38]. These practice-based pharmacists (PBP) are per-
haps ideally placed to deliver the medication review; they
have access to records and the autonomy to change the
repeat template particularly if an independent prescriber.
Involving such PBPs in the delivery of the medication re-
view could address some of the feasibility issues identi-
fied and is a hypothesis for a future trial. Yet this area
may be outside the scope of their practice and compe-
tency. Future research should explore the best way for
pharmacy staff to deliver this specialist medication re-
view and the training requirements.
Conclusion
The feasibility study contained two linked elements; staff
training and medication review. We found it feasible to
develop, deliver and evaluate a well-received staff training
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The dual intervention appeared to increase the ability of
care staff to manage BPSD appropriately with less reliance
on medication. Although we found a clear need for spe-
cialist medication review of psychotropics for care home
residents with dementia, the medication review would re-
quire significant modification for full trial.
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